Hepatitis A

• Shifting hepatitis A epidemiology.
  Kuehn B. JAMA. 2018 Dec 25;320(24):2522.
• Hepatitis A virus prevention and vaccination within and outside the VHA in light of recent outbreaks.
  Moon A, Lowy E, Maier M, et al. Fed Pract. 2018 March;35(2):S32-S37.

Hepatitis B

• Achieving excellence in hepatitis B virus care for Veterans in the VHA.
  Chartier M, Maier M, Morgan T, et al. Fed Pract. 2018 March;35(2):S49-S52.
• Hepatitis B cure: From discovery to regulatory approval.
  Lok AS, Zoulim F, Dusheiko G, et al. J Hepatol. 2017 Oct;67(4):847-861.
• Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
  Belperio PS, Shahoumian TA, Mole LA, et al. Hepatology. 2017 Jul;66(1):27-36.
• Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
  Bersoff-Matcha SJ, Cao K, Jason M, et al. Ann Intern Med. 2017 Jun 6;166(11):792-798.
• Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions.
  Loomba R, Liang TJ. Gastroenterology. 2017 May;152(6):1297-1309.
• Hepatitis B reactivation: the controversies continue.
  Feld JJ. Dig Dis. 2017;35(4):351-358.
• Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
  Hunt CM, Beste LA, Lowy E, et al. World J Gastroenterol. 2016 May 21;22(19):4732-40. (scholarly work supported by VA Liver Disease Database)
• AASLD guidelines for treatment of chronic hepatitis B.
  Terrault NA, Bzowej NH, Chang KM, et al; American Association for the Study of Liver Diseases. Hepatology. 2016 Jan;63(1):261-83.
• Screening high risk individuals for hepatitis B: physician knowledge, attitudes, and beliefs
  Foster T, Hon H, Kanwal F, et al. Dig Dis Sci. 2011 Dec;56(12):3471-87. Epub 2011 Oct 15.
• Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey
  Ioannou GN. Ann Intern Med. 2011 Mar 1;154(5):319-28.
• Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection
  Shamliyan TA, Johnson JR, Macdonald R, et al. J Gen Intern Med. 2011 Mar;26(3):326-39.
• Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment
  Juday T, Tang H, Harris M, et al. J Gen Intern Med. 2011 Mar;26(3):239-44.
• Hepatitis B--more treatments, more testing, not enough data
  Fox, RK. J Gen Intern Med. 2011 Mar;26(3):232-3.
• Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time
  Tai DI, Lin SM, Sheen IS, et al. Hepatology. 2009 Feb; 49(6):1859-1867.
• National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B
  Sorrell MF, Belongia EA, Costa J, et al. Ann Intern Med. 2009 Jan 20;150(2):104-10.
• Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health consensus development conference
  Shamliyan TA, MacDonald R, Shaukat A, et al. Ann Intern Med. 2009 Jan 20;150(2):111-24. Review.
• Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008
  Thompson ND, Perz JF, Moorman AC, Holmberg SD. Ann Intern Med. 2009 Jan 6;150(1):33-9. Review.

Hepatitis C

Epidemiology and Natural Science

• Current state of hepatitis C care in the VA.
  Backus L, Dickson D, Ho S, et al. Fed Pract. 2018 March;35(2):S8-S12.
• Hepatitis C virus infection among women giving birth--Tennessee and United States, 2009-2014.
  Patrick SW, Bauer AM, Warren MD, et al. MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):470-473.
• The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.
  Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. Ann Intern Med. 2012 Feb 21;156(4):271-8.
• Medicine and the epidemic of incarceration in the United States
  Rich JD, Wakeman SE, Dickman SL. N Engl J Med. 2011 Jun 2;364(22):2081-3.
• The healthcare burden imposed by liver disease in aging Baby Boomers.
  Davis GL, Roberts WL. Curr Gastroenterol Rep. 2010 Feb;12(1):1-6.
• Diagnosis, management, and treatment of hepatitis C: an update
  Ghany MG, Strader DB, Thomas DL, et al. Hepatology. 2009 Apr;49(4):1335-74.
• A functional genomic screen identifies cellular cofactors of hepatitis C virus replication
  Tai AW, Benita Y, Peng LF, et al. Cell Host Microbe. 2009 Mar 19;5(3):298-307.
• Elevated prevalence of hepatitis C infection in users of United States veterans medical centers
  Dominitz JA, et al. Hepatology. 2005;41:88-96.
• Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest
  Sloan KL, et al. J Clin Gastroenterol. 2004 Mar;38(3):279-84.
• CDC: Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites -- Connecticut, 1999
  Morbidity and Mortality Weekly Report, July 13, 2001.
• CDC: Hepatitis C virus infection among firefighters, emergency medical technicians, and paramedics -- selected locations, United States, 1991-2000
  Morbidity and Mortality Weekly Report, July 28, 2000.

Prevention and Transmission

• Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study
  Terrault NA, Dodge JL, Murphy EL, et al. Hepatology. 2013 Mar;57(3):881-9.
• Transmission of hepatitis C virus infection through tattooing and piercing: a critical review
  Tohme RA and Holmberg SD. Clin Infect Dis. 2012 Apr;54(8):1167-78. Epub 2012 Jan 30.
• Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008
  Thompson ND, Perz JF, Moorman AC, Holmberg SD. Ann Intern Med. 2009 Jan 6;150(1):33-9. Review.

Testing and Counseling

• Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care
  Backus LI, Belperio PS, Loomis TP, et al. JAMA Intern Med. 2013 Sep 9;173(16):1549-52.
• Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement
  Annals of Internal Medicine, Published online 25 June 2013
• Expanded hepatitis C virus screening recommendations promote opportunities for care and cure (editorial)
  Annals of Internal Medicine, Published online 25 June 2013
• Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement (Patient Summary)
  Annals of Internal Medicine, Published online 25 June 2013
• Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965
  Morbidity and Mortality Weekly Report: Recommendations and Reports, August 17, 2012 / 61(RR04);1-18
• ACIP immunization update
  Campos-Outcalt D. J Fam Pract. 2012 Mar;61(3):150-2.
• The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. Primary care settings
  Rein DB, Smith BD, Wittenborn JS, et al. Ann Intern Med. 2012 Feb 21;156(4):263-70. Epub 2011 Nov 4.
• Economic model of a birth cohort screening program for hepatitis C virus
  McGarry LJ, Pawar VS, Parekh HH, et al. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25510. [Epub ahead of print]
• HCV screening practices and prevalence in an MCO, 2000-2007
  Roblin DW, Smith BD, Weinbaum CM, Sabin ME. Am J Manag Care. 2011;17(8):548-55.
• Screening for hepatitis C virus infection: A review of the evidence for the US Preventive Services Task Force
  Chou, R, et al. Ann Intern Med. 2004 Mar 16;140(6):465-79.

Clinical Management

• Utilizing clinical pharmacist specialist to manage hepatitis C virus patients on direct-acting antiviral therapy.
  Mikolas LA, Jacques K, Huq M, et al. J Pharm Pract. 2018 Jan 1:897190018777345.
• Curing hepatitis C virus infection: best practices from the U.S. Department of Veterans Affairs.
  Belperio PS, Chartier M, Ross DB, et al. Ann Intern Med. 2017 Oct 3;167(7):499-504.
• Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease.
  Backus LI, Belperio PS, Shahoumian TA, et al. Hepatology. 2017 Jul 27. [Epub ahead of print].
• Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge.
  De Monte A, Courjon J, Anty R, et al. J Clin Virol. 2016 May;78:27-30.
• Primary care physician perspectives on hepatitis C management in the era of direct-acting antiviral therapy.
  Thomson M, Konerman MA, Choxi H, et al. Dig Dis Sci. 2016 Mar 8. [Epub ahead of print].
• Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
  Fried MW, Navarro VJ, Afdhal N, et al; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. JAMA. 2012 Jul 18;308(3):274-82.
• Pegylated interferon-associated retinopathy is frequent in HCV patients with hypertension and justifies ophthalmologic screening
  Vujosevic S, Tempesta D, Noventa F, et al. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25654. [Epub ahead of print].
• Outcomes of treatment for hepatitis C virus infection by primary care providers
  Arora S, Thornton K, Murata G, et al. N Engl J Med. 2011 Jun 9;364(23):2199-207. Epub 2011 Jun 1.
• Ensuring equal access to specialty care. [Editorial]
  Sequist TD. N Engl J Med. 2011 Jun 9;364(23):2258-9. Epub 2011 Jun 1.
• Clinical practice. Chronic hepatitis C infection.
  Rosen HR. N Engl J Med. 2011 Jun 23;364(25):2429-38.
• Significant Reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic
  Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. Psychosomatics. 2010 Mar;51(2):149-56.
• Diagnosis, management, and treatment of hepatitis C: an update
  Ghany MG, Strader DB, Thomas DL, et al. Hepatology. 2009 Apr;49(4):1335-74.
• Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.
  Uto H, Stuver SO, Hayashi K, et al. Hepatology. 2009 Apr 1;50(2):393-399.
• Liver biopsy
  AASLD Position Paper; Rockey DC, Caldwell SH, Goodman ZD, et al. Hepatology. 2009 Mar;49(3):1017-44.
• Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study
  Addolorato G, et al. Lancet. 2007 Dec 8;370(9603):1915-22.
• Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis (AASLD Practice Guidelines)
  Garcia-Tsao G, et al. Hepatology. 2007 Sep;46(3):922-38.
• Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis
  Chen CM, et al. Alcohol Clin Exp Res. 2007 Feb;31(2):285-92.
• Risks of a range of alcohol intake on hepatitis C-related fibrosis
  Monto A, et al. Hepatology. 2004 Mar;39(3):826-34.
• Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C
  Siddiqui U, et al. J Clin Gastroenterol. 2004 Aug;38(7):605-10.
• Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review
  Coon JT and Ernst E. J Hepatol. 2004 Mar;40(3):491-500.
• Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
  Ferenci P, Scherzer TM, Kerschner H, et al. Gastroenterology. 2008 Nov;135(5):1561-7.

Treatment

• Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
  Belperio PS, Shahoumian TA, Mole LA, et al. Hepatology. 2017 Jul;66(1):27-36.
• Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System.
  Ioannou GN, Beste LA, Chang MF, et al. Gastroenterology. 2016 Sep;151(3):457-471.e5.
• Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
  Charlton M, Everson GT, Flamm SL, et al; SOLAR-1 Investigators. Gastroenterology. 2015 Sep;149(3):649-59.
• Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1
  Naggie S, Cooper C, Saag M, et al; ION-4 Investigators. N Engl J Med. 2015 Aug 20;373(8):705-13.
• Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection
  Gerber L, Estep M, Stepanova M, et al. Clin Gastroenterol Hepatol. 2016 Jan;14(1):156-164.e3.
• Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection
  Gane EJ, Hyland RH, An D, et al. Gastroenterology. 2015 Nov;149(6):1454-1461.e1.
• Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial
  Sulkowski MS, Eron JJ, Wyles D, et al. JAMA. 2015 Mar 24-31;313(12):1223-31.
• Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
  Hézode C, Asselah T, Reddy KR, et al. Lancet. 2015 Jun 20;385(9986):2502-9.
• Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
  Curry MP, O'Leary JG, Bzowej N, et al; ASTRAL-4 Investigators. N Engl J Med. 2015 Dec 31;373(27):2618-28.
• Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
  Foster GR, Afdhal N, Roberts SK, et al; ASTRAL-2 Investigators; ASTRAL-3 Investigators. N Engl J Med. 2015 Dec 31;373(27):2599-607.
• Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
  Feld JJ, Jacobson IM, Hézode C, et al; ASTRAL-1 Investigators. N Engl J Med. 2015 Dec 31;373(27):2608-17.
• Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
  Forns X, Gordon SC, Zuckerman E, et al. J Hepatol. 2015 Sep;63(3):564-72.
• Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
  Rockstroh JK, Nelson M, Katlama C, et al. Lancet HIV. 2015 Aug;2(8):e319-27.
• Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE
  Buti M, Gordon SC, Zuckerman E, et al. Clin Infect Dis. 2016 Jan 1;62(1):32-6.
• Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial
  Zeuzem S, Ghalib R, Reddy KR, et al. Ann Intern Med. 2015 Jul 7;163(1):1-13.
• Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a U.S. treatment-naive population
  Chahal HS, Marseille EA, Tice JA, et al. JAMA Intern Med. 2015 Nov 23:1-9. [Epub ahead of print]
• Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans
  Backus LI, Belperio PS, Shahoumian TA, et al. Aliment Pharmacol Ther. 2015 Sep;42(5):559-73.
• Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
  Bourliere M, Bronowicki JP, de Ledinghen V, et al. Lancet Infect Dis. 2015 Apr;15(4):397-404.
• Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
  Wyles D, Pockros P, Morelli G, et al. Hepatology. 2015 Apr 2. doi: 10.1002/hep.27814. [Epub ahead of print]
• Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial
  Sulkowski MS, Eron JJ,Wyles D, et al. JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328.
• Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection
  Osinusi A, Townsend K, Kohli A, et al. JAMA. 2015 Mar 24-31;313(12):1232-9. doi: 10.1001/jama.2015.1373.
• Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
  Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218.
• Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
  Zeuzem S, Jacobson IM, Baykal T, et al. N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
• Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
  Feld JJ, Kowdley KV, Coakley E, et al. N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
• ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
  Poordad F, Hezode C, Trinh R, et al. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
• ABT-450, Ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
  Andreone P, Colombo MG, Enejosa JV, et al. Gastroenterology. 2014 Aug;147(2):359-365.e1. doi: 10.1053/j.gastro.2014.04.045. Epub 2014 May 9.
• ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
  Ferenci P1, Bernstein D, Lalezari J, et al; PEARL-III Study; PEARL-IV Study. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
  Kowdley KV, Gordon SC, Reddy KR, et al; ION-1 Investigators. N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
  Afdhal N, Reddy KR, Nelson DR, et al; ION-1 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
  Afdhal N, Zeuzem S Kwo P, et al; ION-1 Investigators. N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.
• Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort
  Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Aliment Pharmacol Ther. 2013 Nov 10. doi: 10.1111/apt.12546. [Epub ahead of print]
• Sofosbuvir for previously untreated chronic hepatitis C infection
  Lawitz E, Mangia A, et al. N Engl J Med. 2013 Apr 23. [Epub ahead of print].
• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
  Jacobson IM, Gordon SC, et al. N Engl J Med. 2013 Apr 23. [Epub ahead of print].
• Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
  Gane EJ et al. N Engl J Med. 2013 Jan 3; 368:34.
• Exploratory study of oral combination antiviral therapy for hepatitis.
  Poordad F. N Engl J Med. 2013 Jan 3; 368:45.
• Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study
  Lo Re V 3rd, Teal V, Localio AR, et al. Ann Intern Med. 2011 Sep 20;155(6):353-60.
• Preliminary study of two antiviral agents for hepatitis C genotype 1
  Lok AS, Gardiner DF, Lawitz E, et al. N Engl J Med. 2012 Jan 19;366(3):216-24.
• Escitalopram for the prevention of peginterferon-a2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial
  Schaefer M, Sarkar R, Knop V, et al. Ann Intern Med. 2012 Jul 17;157(2):94-103.
• Telaprevir for previously untreated chronic hepatitis C virus infection
  Jacobson IM, McHutchison JG, Dusheiko G, et al. N Engl J Med. 2011 Jun 23;364(25):2405-16.
• Telaprevir for retreatment of HCV infection
  Zeuzem S, Andreone P, Pol S, et al. N Engl J Med. 2011 Jun 23;364(25):2417-28.
• Boceprevir for untreated chronic HCV genotype 1 infection
  Poordad F, McCone J Jr, Bacon BR, et al. N Engl J Med. 2011 Mar 31;364(13):1195-206.
• Boceprevir for previously treated chronic HCV genotype 1 infection
  Bacon BR, Gordon SC, Lawitz E, et al. N Engl J Med. 2011 Mar 31;364(13):1207-17.
• Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C
  Marcellin P, Forns X, Goeser T, et al. Gastroenterology. 2011 Feb;140(2):459-468.
• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
  Kwo PY, Lawitz EJ, McCone J, et al. Lancet. 2010 Aug 28;376(9742):705-16.
• Telaprevir for previously treated chronic HCV infection
  McHutchison JG, Manns MP, Muir AJ, et al. N Engl J Med. 2010 Apr 8;362(14):1292-303.
• Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
  Rumi MG, Aghemo A, Prati GM, et al. Gastroenterology. 2010 Jan;138(1):108-15.
• Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
  Ascione A, De Luca M, Tartaglione MT, et al. Gastroenterology. 2010 Jan;138(1):116-22.
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
  McHutchison JG, Lawitz EJ, Shiffman ML, et al. N Engl J Med. 2009 Aug 6;361(6):580-93.
• Effect of hepatitis C virus and its treatment on survival
  Butt AA, Wang X, Moore CG. Hepatology. 2009 Jul 9;50(2):387-392.
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
  McHutchison JG, Everson GT, Gordon SC, et al. N Engl J Med. 2009 Apr 30;360(18):1827-38.
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
  Hészode C, Forestier N, Dusheiko G, et al. N Engl J Med. 2009 Apr 30;360(18):1839-50.
• Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients
  George SL, Bacon BR, Brunt EM, et al. Hepatology. 2009 Mar;49(3):729-38.
• Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
  Rodriguez-Torres M, et al; Latino Study Group. N Engl J Med. 2009 Jan 15;360(3):257-67.
• Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
  Di Bisceglie AM, et al. N Engl J Med. 2008 Dec 4;359(23):2429-41.
• Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study
  Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Am J Public Health. 2008 May;98(5):846-52.

Hepatitis C and Associated Diseases

• Integrating care for patients with chronic liver disease and mental health and substance use disorders.
  Patel K, Maguire E, Chartier M, et al. Fed Pract. 2018 March;35(2):S14-S23.
• Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus.
  Hum J, Jou JH, Green PK, et al. Diabetes Care. 2017 Sep;40(9):1173-1180.
• Liver fibrosis scores predict liver disease mortality in the United States population.
  Unalp-Arida A, Ruhl CE. Hepatology. 2017 Jul;66(1):84-95.
• Screening for diabetes and prediabetes
  Kenealy T, Elley CR, Arroll B. Lancet. 2007 Dec 8;370(9603):1888-9.
• Do high lipids help clearance of hepatitis C?
  Ryder S. Gut. 2007 Aug;56(8):1044-5.
• Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication
  Huang JF, Dai CY, Hwang SJ, et al. Am J Gastroenterol. 2007 Jun;102(6):1237-43.

HIV Coinfection

• Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients
  Poizot-Martin I, Naqvi A, Obry-Roguet V, et al; Hepadat'AIDS Study Group. PLoS One. 2015 Oct 21;10(10):e0141164. doi: 10.1371/journal.pone.0141164.
• The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
  Ioannou GN, Bryson CL, Weiss NS, et al. Hepatology. 2013 Jan;57(1):249-57.
• Management of chronic hepatitis C virus infection in HIV-infected patients
  Pol S, Soriano V. Clin Infect Dis. 2008 Jul 1;47(1):94-101.
• HIV and Liver Disease Forum: Conference Proceedings [pdf]
  Kenneth E. Sherman, KE, et al. Hepatology. 2007 Jun;45(6):1566-77.
• Viral hepatitis in HIV infection
  Koziel MJ, Peters MG. N Engl J Med. 2007 Apr 5;356(14):1445-54.
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
  Carrat F, Bani-Sadr F, Pol S, et al. JAMA. 2004 Dec 15;292(23):2839-48.
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
  Laguno M, Murillas J, Blanco JL, et al. AIDS. 2004 Sep 3;18(13):F27-36.
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
  Torriani FJ, et al. N Engl J Med. 2004 Jul 29;351(5):438-50.
• Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
  Chung RT, et al. N Engl J Med. 2004 Jul 29;351(5):451-9.

Cirrhosis

• Advance care planning (ACP) for specialists managing cirrhosis: a focus on patient-centered care.
  Brisebois A, Ismond KP, Carbonneau M, et al. Hepatology. 2018 May;67(5):2025-2040.
• Trends in 30-day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013.
  Kanwal F, Tansel A, Kramer JR, et al. Am J Gastroenterol. 2017 Aug;112(8):1287-1297.
• Use of antibiotics among patients with cirrhosis and upper gastrointestinal bleeding is associated with reduced mortality.
  Moon AM, Dominitz JA, Ioannou GN, et al. Clin Gastroenterol Hepatol. 2016 Jun 14. [Epub ahead of print] (scholarly work supported by VA Liver Disease Database)
• Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.
  Beste LA, Leipertz SL, Green PK, et al. Gastroenterology. 2015 Nov;149(6):1471-1482.(scholarly work supported by VA Liver Disease Database)
• Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence.
  Poordad F, Schiff ER, Vierling JM, et al. Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446. [Epub ahead of print]
• Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)
  Leroy V, Angus P, Bronowicki JP, et al. Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473. [Epub ahead of print]
• Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia
  Afdhal NH, Giannini EG, Tayyab G et al; ELEVATE Study Group. N Engl J Med. 2012 Aug 23;367(8):716-24.
• Does this patient with liver disease have cirrhosis?
  Udell JA, Wang CS, Tinmouth J et al. JAMA. 2012 Feb 22;307(8):832-42.
• Rifaximin treatment in hepatic encephalopathy
  Bass NM, Mullen KD, Sanyal A et al. N Engl J Med. 2010 Mar 25;362(12):1071-81.
• Management of varices and variceal hemorrhage in cirrhosis
  Garcia-Tsao, G, and Bosch, J. N Engl J Med. 2010 Mar 4;362(9):823-32.
• The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club
  Moore KP, Wong F, Gines P, et al. Hepatology. 2003;38:258-66.

Hepatocellular Carcinoma

• The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015.
  Global Burden of Disease Liver Cancer Collaboration. JAMA Oncol. 2017 Oct 5. [Epub ahead of print]
• Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
  Beste LA, Green PK, Berry K, et al. J Hepatol. 2017 Jul;67(1):32-39.
• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
  El-Khoueiry AB, Sangro B, Yau T, et al. Lancet. 2017 Jun 24;389(10088):2492-2502.
• Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality.
  Serper M, Taddei TH, Mehta R, et al; VOCAL Study Group. Gastroenterology. 2017 Jun;152(8):1954-1964.
• Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.
  Goldberg DS, Taddei TH, Serper M, et al. Hepatology. 2017 Mar;65(3):864-874.
• Hepatocellular carcinoma surveillance: The road ahead.
  Hernaez R, El-Serag HB. Hepatology. 2017 Mar;65(3):771-773.
• Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
  Lai CL, Yuen MF. Hepatology. 2013 Jan;57(1):399-408.
• Screening for liver cancer: the rush to judgment
  Lederle FA, Pocha C. Ann Intern Med. 2012 Mar 6;156(5):387-9.
• Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007
  Thein HH, Walter SR, Gidding HF, et al. J Viral Hepat. 2011 Jul;18(7):e232-41. doi: 10.1111/j.1365-2893.2011.01440.x. Epub 2011 Feb 17.
• Current concepts: hepatocellular carcinoma
  El-Serag, HB. N Engl J Med 2011;365:1118-27.
• Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States
  Davila JA, Henderson L, Kramer JR, et al. Ann Intern Med. 2011 Jan 18;154(2):85-93.
• Hepatocellular Carcinoma in Veterans: Are We Prepared for an Epidemic?
  Pocha, C. Fed Practitioner. 2010 July; 27: Suppl(6).
• Managing Hepatocellular Carcinoma: The Nurse's Role
  Gholz, R and Engstrom, C. Fed Practitioner. 2010 Jan; 27: Suppl(1).
• Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
  Report from the Institute of Medicine, Jan 11, 2010
• Managing Advanced Hepatocellular Carcinoma
  Divekar R, Mehta P, El-Serag H, et al. Fed Pract. 2009 May;26(suppl 1):1-24B.
• Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, et al. N Engl J Med. 2008 Jul 24;359(4):378-90.
• Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study
  Ikeda K, et al. Ann Intern Med. 2007 May 1;146(9):649-56.
• Hepatocellular cancer: a guide for the internist
  Parikh S, Hyman D. Am J Med. 2007 Mar;120(3):194-202. Review.
• Management of Hepatocellular Carcinoma. (AASLD Practice Guideline)
  Bruix J and Sherman M. Hepatology. 2005 Nov;42(5):1208-36.

Liver Transplant

• Access to transplant care and services within the Veterans Health Administration
  Gunnar W, Bronson DA, Cupples SA. Fed Pract. 2018 August;35(8):12-21.
• When to consider liver transplant during the management of chronic liver disease
  Fox RK. Med Clin North Am. 2014 Jan;98(1):153-68.
• Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era
  Olthoff KM, et al. Liver Transpl. 2004 Oct;10(10 Suppl 2):A6-22.
• Comparative analysis of outcome following liver transplantation in US veterans
  Austin GL, et al. Am J Transplant 2004 May;4(5):788-95.
• Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C
  Wiesner RH, et al. Liver Transpl. 2003 Nov;9(11):S1-9.

Transgender Patients

• Mental health and medical health disparities in 5135 transgender veterans receiving healthcare in the Veterans Health Administration: a case-control study
  Brown GR, Jones KT. LGBT Health. 2015 Dec 16. [Epub ahead of print]
• HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
  Deutsch MB, Glidden DV, Sevelius J, et al; iPrEx investigators. Lancet HIV. 2015 Dec;2(12):e512-9.